Effect and Mechanism of Metformin in Endometrial Adenocarcinoma Patients with Metabolic ;Syndrome
NI Juan
SHOU Hua-feng
LOU Han-mei
Abstract：Metformin as the first-line drugs, play an important role in the treatment of diabetes. Metabolic syndrome (MS) is a pathological condition of abnormal aggregation of multiple metabolite resulting. The long-term adverse outcomes were payed more and more attention by people. The study found, MS is recognized risk factor of endometrial adenocarcinoma, there may be a common pathophysiological basis of insulin resistance. Metformin reduces insulin resistance, regulates the level of cytokines and exerts anti-tumor stem cell function, it is a potent inhibitor of metabolic syndrome and endometrial adenocarcinoma.
Keywords：MetforminMetabolic syndrome XEndometrial neoplasmsTherapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 603-605 )